Cantor Fitzgerald Comments on bluebird bio FY2025 Earnings

bluebird bio, Inc. (NASDAQ:BLUE) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for bluebird bio in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the biotechnology company will earn ($23.60) per share for the year. The consensus estimate for bluebird bio’s current full-year earnings is ($27.17) per share.

A number of other research firms also recently commented on BLUE. Barclays increased their price objective on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, December 31st. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $80.00 price target on shares of bluebird bio in a research report on Friday, November 15th. Bank of America lowered bluebird bio from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $60.00 to $10.00 in a report on Friday, November 15th. JPMorgan Chase & Co. downgraded bluebird bio from a “neutral” rating to an “underweight” rating in a report on Friday, November 15th. Finally, Wells Fargo & Company decreased their target price on bluebird bio from $60.00 to $40.00 and set an “equal weight” rating for the company in a research report on Wednesday, September 25th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $49.14.

bluebird bio Stock Down 3.7 %

BLUE stock opened at $7.84 on Wednesday. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. The firm has a 50 day simple moving average of $8.13 and a 200-day simple moving average of $12.00. The company has a market capitalization of $76.20 million, a P/E ratio of -0.21 and a beta of 0.68. bluebird bio has a twelve month low of $5.80 and a twelve month high of $38.40.

Institutional Investors Weigh In On bluebird bio

Several large investors have recently added to or reduced their stakes in BLUE. State Street Corp grew its position in shares of bluebird bio by 1.1% during the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock worth $1,996,000 after acquiring an additional 43,382 shares during the last quarter. Rhumbline Advisers grew its position in bluebird bio by 25.4% in the 2nd quarter. Rhumbline Advisers now owns 292,436 shares of the biotechnology company’s stock worth $288,000 after purchasing an additional 59,219 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of bluebird bio by 152.4% in the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 74,185 shares during the period. Captrust Financial Advisors raised its holdings in shares of bluebird bio by 48.2% during the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 77,293 shares during the last quarter. Finally, Verition Fund Management LLC acquired a new position in shares of bluebird bio during the third quarter worth approximately $42,000. 87.43% of the stock is owned by institutional investors and hedge funds.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.